Wedbush Bullish on Nuvation Bio (NUVB) As NUVB Expands Safusidenib Rights

Nuvation Bio Inc. (NYSE:NUVB) secures a spot on our list of the best penny stocks set to explode.

Wedbush Bullish on Nuvation Bio (NUVB) As NUVB Expands Safusidenib Rights

As of April 8, 2026, over 90% of covering analysts maintain their “Buy” ratings for Nuvation Bio Inc. (NYSE:NUVB), and the consensus price target of $12 implies an upside of 166.08%.

On April 2, 2026, Wedbush maintained its “Buy” rating and $11 price target, providing a favorable backdrop as Nuvation Bio Inc. (NYSE:NUVB) expanded its strategic reach the day before.

On April 1, 2026, Nuvation Bio Inc. (NYSE:NUVB) added Japan rights to its exclusive license deal with Daiichi Sankyo. This would grant the company the sole right to develop and market safusidenib worldwide.

This development strengthens Nuvation Bio Inc. (NYSE:NUVB)’s capacity to support further publication and regulatory development in IDH1-mutant glioma by enabling the ongoing Phase 3 SIGMA study to extend into Japan and providing access to all current and future data. As a maintenance treatment for high-risk astrocytoma, safusidenib, an oral selective mutant IDH1 inhibitor, has demonstrated encouraging efficacy, including long-lasting responses and extended progression-free survival in Phase 1 and 2 trials.

Nuvation Bio Inc. (NYSE:NUVB) is a biopharmaceutical company developing new treatments for difficult-to-treat cancers. The company was founded by David Hung in 2018, and its headquarters are in New York City.

While we acknowledge the risk and potential of NUVB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NUVB and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.